GalactoseL-001-2mg
RPL-αGal
- Specificity
- Terminal α-linked Galactose & N-Acetylgalactosamine (GalNAc)
- Pack size
- 2 mg
- MW
- 14,161 Da (monomer)
- Oligomeric state
- Dimer under physiological conditions, PBS pH 7.2
Recombinant Prokaryotic Lectins · Dublin, Ireland
Recombinant Prokaryotic Lectins for precise glycoanalysis and glycopurification
GlycoSeLect develops high-specificity RPL products that enable simple, fast and efficient detection, analysis, separation and purification of intact glycosylated biomolecules.
Recombinant Prokaryotic LectinsGlycan-specific recognitionGlycoanalysisGlycopurificationBioaffinity separationDublin City University
RPL workflowSEQ · 001
- 01
Glycan target
Intact glycosylated biomolecule presenting a specific epitope.
- 02
RPL recognition
Glycan-selective binding by the recombinant prokaryotic lectin.
- 03
Detection / analysis
Signal via anti-His detection on standard analytical platforms.
- 04
Separation / purification
Immobilised RPL on solid support for selective isolation.
11 RPL productsα / β-Galactoseα-Mannoseα2-3 Sialic acidα-FucosePoly-His taggedAnti-His detectionScalable purification
What we do
Glycan-specific bioaffinity tools for modern biopharmaceutical workflows
GlycoSeLect Ltd specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs) — glycoselective bioaffinity compounds that recognise and bind specific glycan structures displayed on glycoproteins and other glycosylated biomolecules. RPLs help detect, analyse, separate and purify intact glycosylated biomolecules, and their recombinant origin provides consistency and scalability that traditional plant or eukaryotic lectins can find difficult to match.
Specific glycan recognition
RPLs bind defined glycan epitopes on intact glycoproteins and other glycosylated biomolecules.
Consistent recombinant production
Recombinant expression enables reproducible, high-quality products with consistent performance.
Fast detection and analysis
Simple anti-His detection integrates with standard analytical platforms, reducing labelling steps.
Scalable separation & purification
Immobilisation on diverse solid support matrices supports analytical and larger-scale workflows.
Technology
Engineered specificity. Consistent performance. Scalable production.
Recombinant production of prokaryotic lectins offers a controlled route to glycoselective bioaffinity reagents, with reproducible quality across batches and clear paths from analytical use to larger-scale purification.
Traditional plant & eukaryotic lectins
Reference- Variable source material
- Broader binding profiles
- May require additional labelling steps
- Limited scalability depending on source and process
- Performance can vary between batches
GlycoSeLect RPLs
Recombinant- Recombinant production
- Enhanced glycan specificity and affinity
- Consistent performance
- Scalable production
- High-quality products
- Poly-histidine tag for simple anti-His detection
- Suitable for analytical and larger-scale purification workflows
Product portfolio
RPL product portfolio
GlycoSeLect has developed a range of RPL products exhibiting specificity and high affinity for glycan epitopes including terminal galactose, mannose, sialic acid and fucose structures.
GalactoseL-002-2mg
RPL-Gal1
- Specificity
- Terminal β-linked Galactose & N-Acetyllactosamine (LacNAc)
- Pack size
- 2 mg
- MW
- 14,066 Da (monomer)
- Oligomeric state
- Dimer under physiological conditions, PBS pH 7.2
GalactoseL-003-2mg
RPL-Gal2
- Specificity
- Terminal α-linked Galactose > N-Acetylgalactosamine (GalNAc)
- Pack size
- 2 mg
- MW
- 14,162 Da (monomer)
- Oligomeric state
- Dimer under physiological conditions, PBS pH 7.2
GalactoseL-004-2mg
RPL-Gal3
- Specificity
- Terminal α-linked Galactose
- Pack size
- 2 mg
- MW
- 14,081 Da (monomer)
- Oligomeric state
- Tetramer under physiological conditions, PBS pH 7.2
GalactoseL-005-2mg
RPL-Gal4
- Specificity
- Terminal β-linked Galactose, N-Acetyllactosamine (LacNAc) & Lewis x (Lex)
- Pack size
- 2 mg
- MW
- 14,595 Da (monomer)
- Oligomeric state
- Tetramer under physiological conditions, PBS pH 7.2
Mannose/FucoseL-006-2mg
RPL-αMan
- Specificity
- Fucose / Mannose: Lewis a (Lea), Lewis x (Lex) & terminal α-mannose
- Pack size
- 2 mg
- MW
- 13,130 Da (monomer)
- Oligomeric state
- Dimer under physiological conditions, PBS pH 7.2
Mannose/FucoseL-007-2mg
RPL-Man2
- Specificity
- Terminal α-mannose
- Pack size
- 2 mg
- MW
- 15,163 Da (monomer)
- Oligomeric state
- Dimer under physiological conditions, PBS pH 7.2
Sialic acidL-008-2mg
RPL-Sia1
- Specificity
- Terminal α2-3-linked Sialic Acid (Neu5Ac) on N- and O-linked glycans
- Pack size
- 2 mg
- MW
- 27,407.14 Da (monomer)
- Oligomeric state
- Monomer under physiological conditions, PBS pH 7.2
Sialic acidL-009-2mg
RPL-Sia2
- Specificity
- Terminal α2-3-linked Sialic Acid (Neu5Ac) on O-linked glycans
- Pack size
- 2 mg
- MW
- 40,725.17 Da (monomer)
- Oligomeric state
- Monomer under physiological conditions, PBS pH 7.2
Sialic acidL-010-2mg
RPL-Sia3
- Specificity
- Terminal α-linked Neu5Ac
- Pack size
- 2 mg
- MW
- 19,584.89 Da (monomer)
- Oligomeric state
- Monomer under physiological conditions, PBS pH 7.2
FucoseL-011-2mg
RPL-Fuc1
- Specificity
- α-linked Fucose
- Pack size
- 2 mg
- MW
- ≈ 35,849 Da (monomer)
Technical note
All RPL products display a poly-histidine tag, enabling simple detection using standard conjugated anti-His detection antibodies and reducing the need for in vitro labelling steps such as biotinylation. Products are available in different pack sizes and can be supplied in larger quantities if required.
Need product guidance?
Contact GlycoSeLect to discuss the most appropriate RPL for your glycan target, analytical platform or purification workflow.
Applications
Applications across analysis, diagnostics, research and purification
01 · Biopharmaceutical
Biopharmaceutical
Our RPLs can be integrated into a wide range of analytical platforms, supporting workflows from product development to production. Their immobilisation on diverse solid support matrices and scalable production provide flexibility for glycoselective bioaffinity-based purification, including larger-scale use.
Discuss biopharma applications02 · Diagnostic & Research
Diagnostic & Research
RPLs provide tools for the identification of novel glycan-based biomarkers and may support new diagnostic approaches. They can also be used for in situ glycan detection and analysis, cell identification and the classification of microorganisms or infectious agents.
Explore research use cases03 · Food industry
Food Industry
RPLs can be used to extract valuable glycoproteins from food industry raw material streams, supporting selective separation and analysis of glycosylated biomolecules.
Discuss food industry applications04 · Cosmetics
Cosmetics
Glycans play an important role in maintaining the structure and health of the skin. RPLs can support skin glycobiology research as biochemical reagents or as part of analytical platforms for detecting and analysing glycosylated biomolecules.
Discuss cosmetics research applicationsWorkflow
From glycan recognition to usable analytical insight
RPL-based workflows can simplify glycoanalysis by enabling targeted recognition of intact glycosylated biomolecules, supporting faster analysis, selective isolation and purification.
- 01Glycosylated biomolecule
- 02Specific glycan epitope
- 03RPL binding
- 04Detection / analysis
- 05Separation / purification
- 06Actionable result
01
02
03
04
05
06
Glycosylated biomolecule
Specific glycan epitope
RPL binding
Detection / analysis
Separation / purification
Actionable result
Resources
Resources and insights
Selected notes, publications and application material from GlycoSeLect's work with recombinant lectins.
Chemists' technique reveals whether antibodies neutralize SARS-CoV-2
A glycan-focused analytical technique applied to viral surface glycoproteins to assess antibody neutralization.
Read moreBio-Layer Interferometry with Recombinant Prokaryotic Lectins
Using RPLs as bioaffinity probes on BLI platforms for label-free glycan analysis.
Read moreRecombinant Prokaryotic Lectins offer improved glycoprotein analysis and purification
How consistent recombinant production translates to reproducible glycan-selective workflows.
Read moreDevelopment of Simple, Rapid & High-Throughput Glycoanalytics for Biopharmaceuticals
Streamlined RPL-based workflows for biopharma glycoprofiling.
Read moreSimplifying Glycoanalysis with Recombinant Prokaryotic Lectins
A practical overview of RPL utility across analytical platforms.
Read moreStreamline Purification of Glycosylated Proteins with Recombinant Prokaryotic Lectins
From analytical selection to scalable bioaffinity purification with immobilised RPLs.
Read moreTeam
Management
RD
Robert Dunne
Chief Executive Officer
B.A. (Mod.), MBA, MICI
Robert is an experienced executive with over 34 years of experience in the pharmaceutical industry, with expertise in business development, operations, regulatory and quality management. He is responsible for the overall management and strategic direction of the company.
IE
Dr Ian Evetts
Director
PhD
Ian has over 20 years' experience in the pharmaceutical industry, gained through senior positions in business development, licensing, sales and marketing across multinational companies and biotech organisations.
NB
Neil Brown
Non-Executive Director
Neil has been a Non-Executive Director of GlycoSeLect for the past 8 years and has over 20 years' experience across banking, state agencies, manufacturing, distribution and services. His background includes corporate finance, mergers and acquisitions, insolvency and restructuring.
SZ
Song Zhiyang
China Representative
Song represents GlycoSeLect in China and has 20 years of working experience within the Chinese pharmaceutical industry, including multinational companies and R&D pharmaceutical associations. Based in Beijing, he supports the introduction of GlycoSeLect's RPL glycan-specific technology to glycobiology researchers.
Advisory
Scientific Advisory Board
A group of scientific advisors supporting GlycoSeLect's strategic and technical direction.
Distribution
Global distribution network
GlycoSeLect products are available through a network of international distributors across Europe, the Americas, Asia-Pacific, the Middle East and Africa.
Australia & New ZealandCanadaChinaGermanyIndiaIsraelItalyKoreaNetherlandsPoland & ScandinaviaSingaporeSouth AfricaSpainSwitzerlandUKUK & USAJapanFrance & Bulgaria
Contact
Contact GlycoSeLect
Reach the team to discuss RPL products, applications, distribution or bespoke requirements.
Address
GlycoSeLect Ltd
Hamilton Building
DCU Campus
Collins Ave Ext, Whitehall
Glasnevin, Dublin 9
Ireland
Phone
+353 1 254 4164
Ready to discuss your glycan target or purification workflow?
Contact GlycoSeLect to explore RPL products for glycoanalysis, glycoprotein detection, separation and purification.